Revolution, Ascendis, Arrowhead among RBC's top M&A candidates in biotech
Source: SeekingAlpha
2026-03-19 14:37:43 ET
More on Revolution Medicines, Ascendis Pharma, etc.
- Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL - Slideshow
- This One Data Readout Could Make Or Break Revolution Medicines
- Ascendis Pharma wins FDA approval for navepegritide for achondroplasia
- Kymera outlines plans for KT-621 Phase IIb data in 2027 as cash runway extends into 2029
Read the full article on Seeking Alpha
For further details see:
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Rhythm Pharmaceuticals Inc.
NASDAQ: RYTM
RYTM Trading
-3.57% G/L:
$79.71 Last:
275,549 Volume:
$81 Open:
RYTM Latest News
March 26, 2026 09:01:56 am
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
March 20, 2026 12:58:00 pm
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
March 19, 2026 06:30:00 pm
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
March 16, 2026 04:01:00 pm
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
RYTM Stock Data
$6,891,165,143
62,665,157
0.73%
95
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
